What question did this study set out to answer?

The study aims to evaluate the effects of empagliflozin after aortic valve replacement.

March 31, 2026Open Access

Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: a randomized clinical trial

Key Result

The EMPAVR randomized clinical trial will investigate the clinical effects of empagliflozin in patients following aortic valve replacement.

Key Points

The study aims to evaluate the effects of empagliflozin after aortic valve replacement.
Randomized clinical trial design.
Participants will provide oral and written informed consent.
The study is approved by ethics and regulatory authorities.
Specific outcomes are yet to be determined as patient enrollment has not yet begun.

Structured PICO

Population

Patients after Aortic Valve Replacement

Intervention

Empagliflozin

This paper describes the design and rationale of the EMPAVR randomized clinical trial evaluating empagliflozin after aortic valve replacement.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

The EMPAVR study was registered in December 2024 (Clinical Trial Registration number: NCT06171802) before enrollment of the first patient. All patients will provide oral and written informed consent. The EMPAVR study is approved by the Regional Committee on Health Research Ethics and the Danish Medicines Agency.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Sørensen et al. (Sun,) reported a other. The EMPAVR randomized clinical trial will investigate the clinical effects of empagliflozin in patients following aortic valve replacement.

synapsesocial.com/papers/69cb63c9e6a8c024954b87f3 https://doi.org/https://doi.org/10.1016/j.ahj.2026.107432